|
US2010204251A1
|
|
Molecular target of neurotoxicity
|
|
WO2009144424A2
|
|
Process and method for diagnosing alzheimer’s disease
|
|
CN101542289A
|
|
Methods and tools for the therapy of neurodegenerative pathologies
|
|
EP2014651A1
|
|
Compounds and methods for modulating Rho GTPases
|
|
EP2044216A2
|
|
Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
|
|
KR20090034932A
|
|
Identification and use of gprc variants in the treatment and diagnosis of parkinson's disease
|
|
AU2007211544A1
|
|
Methods of treating degenerative disorders with Rac 1b inhibitor
|
|
US2009269744A1
|
|
Cancer detection method
|
|
FR2900936A1
|
|
Method and methods for detecting alzheimer's disease
|
|
EP1835036A1
|
|
Methods and compositions for the detection and treatment of cancers
|
|
EP1786906A2
|
|
Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
|
|
US2007027146A1
|
|
Methods of treating nervous disorders
|
|
EP1746092A1
|
|
Compounds and methods for treatment of amyloid-B-peptide related disorders
|
|
EP1656931A1
|
|
Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
|
|
EP1692310A2
|
|
Identification of diagnostic markers for communicable subacute spongiform encephalopathies
|
|
WO2005045021A1
|
|
Bace455, an alternative splice variant of the human beta-secretase
|
|
EP1636379A2
|
|
Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
|
|
US2005043319A1
|
|
Molecular target of neurotoxicity
|
|
EP1586587A1
|
|
Compositions and methods for detecting angiogenesis
|
|
EP1541549A1
|
|
Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
|
